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oo the Editor: Pulsatile ventricular assist device (VAD) support
s an effective and widely used treatment strategy for the manage-
ent of unstable cardiac transplant candidates and has recently
een approved by the Food and Drug Administration as a suitable
lternative treatment for patients who are not candidates for heart
ransplantation. The approval was borne out of results of the
andomized Evaluation of Mechanical Assistance in Treatment of
hronic Heart Failure trial, which demonstrated significant sur-
ival and quality-of-life benefits for recipients of the HeartMate
AD (Thoratec Corp., Pleasanton, California) as compared to an
ptimally medically treated cohort (1). This trial underscored the
ignificant limitations of pulsatile technology, including the large
ize of the devices and the high incidence of device-related
nfection and malfunction.
In an effort to address several of these shortcomings, the
icroMed DeBakey VAD (MicroMed Technology Inc., Houston,
exas), an axial flow pump (2), has been undergoing clinical
valuation as a bridge to transplantation. The present study details
he results of the recently completed safety and feasibility trial with
his device in the U.S.
Study patients were in New York Heart Association functional
lass IV, were inotrope and/or intra-aortic balloon pump depen-
ent, and were accepted as candidates for cardiac transplantation.
he demographic and clinical profile of the patients is depicted in
able 1.
Details of the pump have been described in detail elsewhere (2).
riefly, the MicroMed DeBakey VAD is a miniaturized, implant-
ble, electromagnetically actuated titanium pump with a single
oving impeller. The rotating motion of the impeller produces
ontinuous flow. An ultrasonic flow probe provides direct mea-
urements of pump flow. Wiring from the pump and the flow
robe exit the skin and connect to a portable controller.
Placement of the device was conducted under full cardiopulmo-
ary bypass (CPB) support without cardioplegic arrest. In all cases,
he VAD inflow was inserted into the left ventricular cavity via the
pex, and the outflow was connected to the aorta.
Post-operatively, all patients received systemic anticoagulation
herapy with intravenous heparin. Coumadin therapy was insti-
uted with a target international normalized ratio of 2.5 to 3.5.
latelet inhibitors were administered to all patients.
Unpaired t tests were used to compare continuous variables
etween survivors and non-survivors. Contingency tables were
sed for categorical variables and compared in all instances with
isher exact test. Univariate analysis was used to identify correlates
f non-survival. A value of p  0.05 was considered significant.
All 30 patients survived the operation. Mean VAD support time
as 42  30 days (range 9 to 111 days). Cumulative support time
as 42 patient-months.
Adverse events included reoperation for bleeding (n  8, 27%),
emolysis (n  3, 10%), device-related infection (n  2, 6.7%),
ump thrombus (n 4, 13%), and stroke (n 3, 10%). There was
o device failure. Twenty patients (67%) were successfully bridged
o transplantation, and 19 were well 30 days after transplantation. aPulsatile VAD systems remain the gold standard for the
reatment of advanced heart failure necessitating advanced me-
hanical support. Clinical experience with these devices (1,3,4) has
nderscored the limitations inherent to these large pumps—
amely, the inability to support small patients, noise, and the high
ates of device infection and malfunction.
Miniaturization of mechanical support technology has resulted
n pumps capable of expanding the pool of patients that can be
upported. Inherent in their design is a limited blood-contacting
urface and the lack of valves, air vents, or compliance chambers.
he MicroMed DeBakey VAD is the most widely tested of these
ew miniaturized devices.
Considerations for participation in the trial included degree of
nd-organ dysfunction, condition of the right ventricle, ability to
olerate chronic anticoagulation, expected transplantation waiting
ime, and the patient’s desire to participate in the trial, among
thers.
End-organ perfusion was maintained, and despite continuous
ow physiology, all recipients regained some pulsatility owing to
mprovement of the left ventricle with unloading.
Bleeding requiring reoperation was the most common adverse
vent seen. Hemolysis occurred rarely and was transient in all three
nstances. Remarkably, the incidence of significant device-related
nfection or malfunction, the two main limitations of pulsatile
echnology, was almost negligible. The low incidence of infection
s likely due to the presence of a low-caliber flexible driveline that
eadily incorporates to the integument, less torque motion, and the
bsence of a large preperitoneal pocket.
Pump thrombus is a problem more often seen with axial flow
echnology and was identified in four patients. In this early
xperience, pump exchange and high doses of plasminogen acti-
ator were used for treatment. None of the patients who developed
ump thrombus suffered a stroke or a clinically obvious peripheral
mbolus.
Not surprisingly, pre-operative dependence on intra-aortic bal-
oon support and mechanical ventilation were strong univariate
redictors of death before transplantation. Longer CPB time was
lso a predictor of death and likely reflects previous surgery,
echnical difficulties, excessive bleeding, and/or right heart dys-
unction.
Patients were able to ambulate connected to their portable
ontroller and battery packs, but otherwise were untethered. The
ursing staff readily became proficient with idiosyncrasies of axial
ow, including the lack of an arterial waveform or a palpable pulse
nd the treatment algorithms for abnormal wave patterns sugges-
ive of ventricular suction.
The trial protocol required that patients remain hospitalized
ntil a suitable donor organ became available. This explains the
elatively short mean support time of 42 days observed in the trial.
verall success with bridging to transplantation was 67%, and 95%
f these patients survived to 30 days after transplantation.
Skepticism surrounding the hemodynamics of continuous flownd the ability to maintain end-organ function has abated as
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March 15, 2005:962–7linical experience with axial flow pumps has grown. Indeed, a
umber of these devices, including the Jarvik Flowmaker (New
ork, New York) (5) and the Incor pump (Berlin, Germany) (6),
re entering clinical trials.
In summary, the results of this first trial of an axial flow pump in
he U.S. suggest that the MicroMed DeBakey VAD can provide
ffective circulatory support in patients with end-stage heart failure.
uccessful bridging to transplantation occurred with a rate similar to
hat currently achieved with time-tested pulsatile technology (4).
As a result of this initial feasibility trial, the FDA has approved
n expanded multicenter evaluation of the MicroMed DeBakey
ump as a bridge to transplantation.
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able 1. Demographic and Clinical Profile of MicroMed
ecipients
Variable n %
ge (yrs)
Mean 53  11
Range 20–69
emale 10 33
ace
Caucasian 19 63
Black 6 20
Hispanic 5 17
tiology of cardiomyopathy
Ischemic 17 57
Idiopathic 13 43
ody surface area (m2)
Mean  SD 1.9  0.2
Range 1.3–2.3
rior sternotomy 16 53
rior stroke 4 13
rior myocardial infarct 17 57
ntra-aortic balloon pump 17 57
echanical ventilation 5 17
2 inotropes 16 53
aseline hemodynamics
Cardiac index (l/min/m2) 1.8  0.5
Pulmonary wedge pressure (mm Hg) 27  9
Systolic blood pressure (mm Hg) 92  11
Diastolic blood pressure (mm Hg) 57  10
aseline end organ function
Blood urea nitrogen (mg/dl) 26  13
Creatinine (mg/dl) 1.3  0.5
Total bilirubin (mg/dl) 1.4  0.9
Plasma free hemoglobin 11  14
Platelet count ( 103/mm3) 225  99
D  standard deviation.doi:10.1016/j.jacc.2004.12.020 sEFERENCES
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etters to the Editor
ptimal Lipids, Statins, and Dementia
e read with interest the excellent and thought-provoking recent
eport in the June 2, 2004, issue of JACC by O’Keefe et al. (1)
uggesting that the optimal low-density lipoprotein (LDL) is 50 to
0 mg/dl. We agree with most of the points in their paper,
articularly regarding the fact that lower levels of LDL may be
ptimal, and we have already routinely implemented getting LDL
evels at least under 80 mg/dl (and often in the range of 50 to 70
g/dl) in patients following acute coronary syndrome (ACS), as
ased on the Thrombolysis In Myocardial Infarction (TIMI)-22
rial (2), and generally are more aggressive than the national goals
or patients with stable atherosclerosis; however, caution is needed
efore routinely recommending levels of LDL of 50 to 70 mg/dl.
lthough it is hard to argue with the investigators’ dietary and
ife-style recommendations (1,3), the use of pharmacologic inter-
ention to achieve these therapeutic targets may be premature. It is
oped that the ongoing intensity trials (TNT, SEARCH,
DEAL, A2Z) will not only provide further insight into this area
ut also provide information on cost-effectiveness of this approach.
n addition, the investigators note that only one-third of vascular
atients are currently reaching the more liberal LDL goal of 100
g/dl, not to mention the fact that most vascular patients also have
ow levels of high-density lipoprotein (HDL) cholesterol and
any have elevated levels of non-HDL cholesterol, both of which
ay need additional treatment (4,5).
The researchers also listed several “unintended” benefits of LDL
owering, one of which was reduction in dementia (1,6). However,
urrent published data are quite conflicting with regards to the
ffects of statins on cognitive function and memory loss. Early
xamination of hospital databases revealed a possible connection
etween statin use and subsequent development of dementia,
here use of lovastatin or pravastatin was associated with a lower
revalence of Alzheimer’s disease (7). Another report from the
nited Kingdom, using a nested case-control study of patients
ged 50 years and older, described an adjusted relative risk of
eveloping dementia among patients receiving statin therapy of
.29 (95% confidence interval, 0.13 to 0.63; p  0.002) (8).
owever, two recent large prospective studies have further assessed
his. The Heart Protection Study (HPS) was the first prospective
tatin study to evaluate cognitive impairment as an outcome of the
